Clinical

Panelists of a session at CHEST 2021 discuss the latest research regarding efficacy and safety of therapies in the management of asthma, including biologics, corticosteroids, and more.

There was statistically significant and clinically meaningful overall survival benefit vs sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC) in top-line results from a phase 3 trial.

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

Individuals who drink more than 3 cups of coffee a day had decreased liver stiffness.

New modeling could help explain why some patients develop resistance to tyrosine kinase inhibitors.

The pathway outlines a 4-step screening process for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

The case suggests lung transplantation can be a feasible option for patients with lung involvement.

New data on treatment for newly diagnosed pulmonary arterial hypertension (PAH) show initial treatment for the progressive disease that includes macitentan has potential to reduce risk of disease progression.

In patients with BRAF-mutated melanoma, achieving a complete response and circulating tumor DNA negativity are promising prognostic markers.

Artificial intelligence (AI) was used to predict response of high-grade extrauterine serous carcinoma (HGSC) to adjuvant platinum chemotherapy.

Acid sphingomyelinase deficiency (ASMD) is a rare lysosomal storage disorder; a new report said that plasma lyso-sphingomyelin levels can be used to not only diagnose the rare disease but also predict severity and type.

Investigators reported comprehensive genomic features of patients with clear cell renal cell carcinoma, potentially giving providers a better understanding of the molecular features associated with the disease.

Dosing from pivotal phase 3 trials of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) is not optimal for real-world patients who experience different efficacy and adverse events (AEs).

Maralixibat is the first treatment approved for cholestatic pruritus in patients with Alagille syndrome who are 1 year or older.

A new study suggests the lower-cost, more patient-friendly assessment method may be a useful tool for clinicians.

Therapies that block adenosine triphosphate (ATP) can reduce the irritation that causes cough, and some currently being studied also don’t have taste side effects that can confound clinical trial results, explained Ron Eccles, BSc, PhD, DSc, emeritus profess at Cardiff University.

Researchers identified the frequency with which acute medication overuse occurs among migraineurs and factors associated with the condition.

This new study adds to the literature by giving the first long-term data in these populations.

A look at the existing literature suggests more questions than answers remain when it comes to the potential use of the cholinergic anti-inflammatory pathway in connective tissue diseases (CTDs).

With the Oncology Care Model (OCM) slated to end in 2022, the successor model is still not in place. According to panelists, there is likely going to be a gap after OCM ends and the new model begins, but more importantly, practices should prepare for the new model to be mandatory.

Study results released earlier this month showcased results in children and adults with uncontrolled asthma. The findings were presented at the European Respiratory Society (ERS) 2021 International Congress.

In the opening sessions at the Patient-Centered Oncology Care® conference, held September 23-24 both virtually and in Nashville, Tennessee, speakers focused on addressing disparities by getting involved and engaged with the community.

The reports suggest patients with rheumatoid arthritis (RA) could experience secondary neurological adverse events, though the side effect appears to be rare.

Intravenous belimumab had benefits, but also resulted in more health care utilization due to the nature of its administration.

A team of Australian researchers created and validated a model that may boost efficiency of type 1 diabetes (T1D) progression screening.